ライフサイエンスコーパス: cholangitis

1 ulosis with features of secondary sclerosing cholangitis.

2 0-year-old female admitted with severe acute cholangitis.

3 uch as alcoholic liver disease or sclerosing cholangitis.

4 d abrogates progression of murine sclerosing cholangitis.

5 ary biliary cirrhosis and primary sclerosing cholangitis.

6 ary biliary cirrhosis and primary sclerosing cholangitis.

7 robials were those with secondary sclerosing cholangitis.

8 d promoted the induction of T-cell-dependent cholangitis.

9 ties, primary (PSC) and secondary sclerosing cholangitis.

10 till rarer is its presentation as sclerosing cholangitis.

11 OT-II/dnTGFbetaRII/Rag1(-/-) mice developed cholangitis.

12 oth before and after induction of autoimmune cholangitis.

13 limb to decrease the risk for postoperative cholangitis.

14 etaRII) with dramatically reduced autoimmune cholangitis.

15 rally considered reflective of an autoimmune cholangitis.

16 ry biliary cirrhosis, and primary sclerosing cholangitis.

17 ls, are required for induction of autoimmune cholangitis.

18 l cells (BECs) in patients with IgG4-related cholangitis.

19 CD4 promoter, develop autoimmune colitis and cholangitis.

20 the steroid-nonresponsive primary sclerosing cholangitis.

21 at is not associated with primary sclerosing cholangitis.

22 mmatory bowel disease compared to autoimmune cholangitis.

23 erved among patients with primary sclerosing cholangitis.

24 equirement for the development of autoimmune cholangitis.

25 the treatment of pruritus in primary biliary cholangitis.

26 udies as risk factors for primary sclerosing cholangitis.

27 ations in patients with secondary sclerosing cholangitis.

28 lymphocytes similar to human primary biliary cholangitis.

29 e of Gal-3 in the murine model of autoimmune cholangitis.

30 y tree, is down-regulated in primary biliary cholangitis.

31 rahepatic cholestasis and primary sclerosing cholangitis.

32 rs may be therapeutic for primary sclerosing cholangitis.

33 ry tissues from mice and patients with AP or cholangitis.

34 cially in patients with secondary sclerosing cholangitis.

35 her than jaundice (11% vs. 30%, P < 0.05) or cholangitis (0% vs. 21%, P < 0.05), to have pancreas div

36 irs when performed by specialists [recurrent cholangitis:11%, 12%, and 10%; P = 0.96, NS; re-strictur

37 iary cirrhosis (16%), and primary sclerosing cholangitis (13%) with an odds ratio of 2.3, 2.1, and 1.

38 Patients died from tumor progression (55%), cholangitis (18%), pneumonia (7%), hemobilia (7%), esoph

39 umerical rating scale (NRS), primary biliary cholangitis-40 (PBC-40) itch domain score and 5-D itch s

40 hepatobiliary (including primary sclerosing cholangitis) (5.5% vs. 0.1%), pancreatic (1.7% vs. 0%) a

41 endent risk factors (P < 0.05) for recurrent cholangitis [50% and 27%], re-stricturing (75% and 61%),

42 (28%), deep incisional infections (8%), and cholangitis (6%).

43 4%) and 114 patients with primary sclerosing cholangitis (62.3%).

44 rimarily indications for ERC were sclerosing cholangitis (75%) and malignant stenosis (9.5%).

45 Importance: Acute cholangitis (AC), particularly severe AC, has historical

46 ne hepatitis (AIH) and autoimmune sclerosing cholangitis (AISC) either through inability of Tregs to

47 rimary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease, and chronic hepati

48 XR, is effective in treating primary biliary cholangitis, an autoimmune liver disease.

49 rimary biliary cirrhosis, primary sclerosing cholangitis and biliary atresia are thought to be immune

50 to determine the incidence of postoperative cholangitis and biliary stricture.

51 is difficult to distinguish from sclerosing cholangitis and biliary/pancreatic malignancies (CA).

52 bile samples from patients with IgG4-related cholangitis and disrupt the TJ-mediated BEC barrier in v

53 trong comorbidity between primary sclerosing cholangitis and inflammatory bowel disease is likely the

54 sporidial infections associated with chronic cholangitis and liver disease.

55 sporidial infections associated with chronic cholangitis and liver disease.

56 Four presented with cholangitis and one with variceal bleeding.

57 ide a rationale to target Gal3 in autoimmune cholangitis and potentially other cholestatic diseases.

58 ile ductular reactions of primary sclerosing cholangitis and primary biliary cirrhosis patient liver

59 iated diseases, including primary sclerosing cholangitis and primary biliary cirrhosis, but not with

60 liver diseases, particularly primary biliary cholangitis and primary sclerosing cholangitis (PSC), ev

61 ew on the pathophysiology of primary biliary cholangitis and PSC in the hope that these new drugs can

62 y samples from 16 patients with IgG4-related cholangitis and respective controls, and evaluated trans

63 ramatic reduction in histological autoimmune cholangitis and significant decreases in levels of intra

64 tween the steroid-responsive IgG4-associated cholangitis and the steroid-nonresponsive primary sclero

65 ohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis to investigate pleiot

66 protein loosing enteropathy, and sclerosing cholangitis and was diagnosed with lymphedema cholestasi

67 ly 7 patients having a history of sclerosing cholangitis and/or inflammatory bowel disease and none w

68 se bilobar congenital IHBDD complicated with cholangitis and/or portal hypertension achieved excellen

69 insic compression from pancreatic cysts, and cholangitis), and 3 with bile leak syndromes.

70 iary tree with low rates of leak, stricture, cholangitis, and bile gastritis.

71 ith autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis as a group ha

72 mune hepatitis, recurrent primary sclerosing cholangitis, and recurrent primary biliary cirrhosis in

73 ive plasma cells ('immunoglobulin associated cholangitis') are part of a spectrum of disorders includ

74 toimmune hepatitis and autoimmune sclerosing cholangitis ASC).

75 ing cholangitis (PSC), autoimmune sclerosing cholangitis (ASC), and autoimmune hepatitis (AIH) are no

76 ly distinguish patients with IgG4-associated cholangitis/autoimmune pancreatitis (n = 34) from those

77 timitochondrial-negative variant, autoimmune cholangitis, being the two autoimmune liver diseases wit

78 ere anastomosis-related complications (leak, cholangitis, bile gastritis, or stricture), and the seco

79 y strictures with time, leading to recurrent cholangitis, biliary cirrhosis, and end-stage liver dise

80 ing parasitic infections, primary sclerosing cholangitis, biliary-duct cysts, hepatolithiasis, and to

81 complications of drainage (choleperitoneum, cholangitis, bleeding, and seeding).

82 ivation in the earliest phases of autoimmune cholangitis but subsequently leads to downregulation of

83 ary strictures resembling primary sclerosing cholangitis but with increased serum immunoglobulin G4 a

84 does not alter the initiation of autoimmune cholangitis, but does contribute to the exacerbation of

85 rosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.

86 Differentiation of primary sclerosing cholangitis can be challenging because other chronic cho

87 role in biliary atresia, primary sclerosing cholangitis, cellular rejection, and primary biliary cir

88 Biliary drainage can cause cholangitis/cholecystitis, pancreatitis, hemorrhage, por

89 ilson's disease) and ICC (biliary cirrhosis, cholangitis, cholelithiasis, choledochal cysts, hepatiti

90 g cholangitis (PSC) suffering from bacterial cholangitis, consensus recommendations published in Dece

91 CCAs and 20 nonmalignant primary sclerosing cholangitis controls), and the methylation status of the

92 validated (34 CCAs and 34 primary sclerosing cholangitis controls).

93 Up to 70% of patients with primary biliary cholangitis develop pruritus (itch) during the course of

94 Likewise, cholangitis developed in mice expressing ovalbumin simul

95 everity using the Tokyo Guidelines for acute cholangitis diagnosis.

96 Three (13.6%) patients developed cholangitis due to occlusion of unrecognized secondary b

97 981 cholangitis episodes from 810 patients were analysed ret

98 dihydrocollidine (DDC; a model of sclerosing cholangitis) for 4 weeks.

99 Primary biliary cholangitis (formerly called primary biliary cirrhosis)

100 pplied for exception points due to bacterial cholangitis from February 27, 2002 to March 14, 2011.

101 Bile samples from patients with IgG4-related cholangitis had significant increases in levels of Th2 c

102 Patients with primary sclerosing cholangitis have a poor prognosis; progression to liver

103 Many patients with primary biliary cholangitis have an inadequate response to first-line th

104 plotype associations with primary sclerosing cholangitis have been investigated.

105 adiologic signs of bile duct obstruction and cholangitis, her blood analysis showed severe unconjugat

106 s (HR 5.11; 3.29-7.96), gallstone disease or cholangitis (HR 2.72; 2.55-2.91, and 4.22; 3.13-5.69, re

107 Immunoglobulin G4 (IgG4)-associated cholangitis (IAC) is a manifestation of the recently dis

108 addition of immunoglobulin (Ig)G4-associated cholangitis (IAC), also called IgG4-related sclerosing c

109 mmune pancreatitis (AIP) and IgG4-associated cholangitis (IAC); a >2-fold increase in sIgG4 is consid

110 Liver histology of sclerosing cholangitis improved, and extent of fibrosis decreased c

111 y to migrate to the liver, where they caused cholangitis in a strictly antigen-dependent manner.

112 d provide the first link between colitis and cholangitis in an antigen-dependent mouse model.

113 Importantly, however, autoimmune cholangitis in dnTGFbetaRII IL-6(-/-) mice was significa

114 ter (ASBT), blocks progression of sclerosing cholangitis in mdr2(-/-) mice.

115 break in tolerance that leads to autoimmune cholangitis in NOD.Abd3 congenic mice.

116 nitiated after the development of autoimmune cholangitis in previously immunized mice, also resulted

117 f Gal-3 significantly exacerbates autoimmune cholangitis in these mice.

118 luences on the natural history of autoimmune cholangitis in this model.

119 h efforts should focus on primary sclerosing cholangitis, in addition to primary biliary cirrhosis an

120 arisen from studies of secondary sclerosing cholangitis, in which a similar clinical profile is asso

121 Symptoms of primary sclerosing cholangitis include fatigue, jaundice, pruritus, or stea

122 n, completely inhibits the manifestations of cholangitis, including AMA production, intrahepatic T-ce

123 angitis, whereas male mice were resistant to cholangitis induction.

124 , we propose to stratify patients with acute cholangitis into a high and low risk group.

125 lps physicians to assign patients with acute cholangitis into different management groups.

126 rs promising to stratify patients with acute cholangitis into different management groups.

127 rimary biliary cirrhosis, primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, or h

128 s (IAC), also called IgG4-related sclerosing cholangitis (IRSC), to the spectrum of chronic cholangio

129 Primary sclerosing cholangitis is a chronic cholestatic liver disease chara

130 Primary sclerosing cholangitis is a chronic immune-mediated liver disease.

131 IgG4-related cholangitis is a chronic inflammatory biliary disease th

132 Primary sclerosing cholangitis is a chronic, progressive cholangiopathy tha

133 Acute cholangitis is a life-threatening bacterial infection of

134 a strengthen the notion that immune-mediated cholangitis is caused by T cells primed in the GALT and

135 Treatment of pruritus in primary biliary cholangitis is challenging and novel therapies are neede

136 Treatment of primary sclerosing cholangitis is confined to supportive measures, but adva

137 r T cells function in the natural history of cholangitis is essential and illustrates that precision

138 e colitis associated with primary sclerosing cholangitis is pathophysiologically distinct from UC tha

139 Primary sclerosing cholangitis is the classic hepatobiliary manifestation o

140 The etiopathogenesis of primary sclerosing cholangitis is unknown.

141 function tests but bilirubin <4 mg/dL and no cholangitis) is a matter of debate.

142 ard first-line treatment for primary biliary cholangitis, is largely ineffective for pruritus.

143 VT, after exclusion of those with sclerosing cholangitis, liver transplants, choledocholithiasis, or

144 compared with normal and primary sclerosing cholangitis livers.

145 included autoimmune pancreatitis, sclerosing cholangitis, lymphoplasmacytic aortitis, salivary gland

146 ator of inflammatory signaling in autoimmune cholangitis, mediating the activation of NLRP3 inflammas

147 Primary sclerosing cholangitis mice and patients have increased MCs.

148 Prior to the induction of autoimmune cholangitis, mice were treated with either anti-CD20, an

149 Immunoglobulin G subtype 4 (IgG4)-associated cholangitis mimics cholangiocarcinoma and presence of mo

150 A BDL-induced acute cholangitis model was characterized by increased relativ

151 26% vs 82%), despite a higher rate of severe cholangitis (n = 131 [67%] vs n = 29 [25%]).

152 (n = 34) from those with primary sclerosing cholangitis (n = 17) and CA (n = 17).

153 5), choledocholithiasis (n = 3), idiopathic cholangitis (n = 2), and deceased donor or live donor li

154 Adverse events were cholangitis (n=4), liver abscess (n=2), cholecystitis (n

155 ry cirrhosis (PBC, n=76), primary sclerosing cholangitis (n=81), hepatitis C virus (HCV) (n=945), alc

156 , disease was a) Sclerosing pancreatitis and cholangitis, n = 21; b) Sclerosing cholangitis, n = 9; c

157 titis and cholangitis, n = 21; b) Sclerosing cholangitis, n = 9; c) Sclerosing pancreatitis, n = 4; d

158 She developed cholangitis, necessitating an emergent endoscopic retrog

159 arising in the setting of primary sclerosing cholangitis, neoadjuvant chemoradiotherapy followed by l

160 Neonatal ichthyosis and sclerosing cholangitis (NISCH) syndrome is a liver disease caused b

161 r situations of intercurrent cholestasis and cholangitis, not for cholestasis in end-stage disease.

162 eries on immunoglobulin G4 (IgG4)-associated cholangitis noted that patients with IgG4-associated cho

163 l-related serious adverse events, most often cholangitis, occurred in 27.3% of patients.

164 A gene did not affect the severity of either cholangitis or colitis, suggesting that the IL-23/Th17 p

165 patients and in those with hypoalbuminemia, cholangitis or long-term jaundice; with an FLR < 30% or

166 Patients with cholangitis or pancreatitis were excluded.

167 llidine (DDC) feeding (a model of sclerosing cholangitis) or bile duct ligation (BDL).

168 rimary biliary cirrhosis, primary sclerosing cholangitis, or alcoholic cirrhosis (group I), NASH, and

169 thiasis, cholecystitis, choledocholithiasis, cholangitis, or biliary pancreatitis), mortality, and co

170 r, anastomosis-related complications (leaks, cholangitis, or strictures) were fewer in the duodenal t

171 3), as well as absence of primary sclerosing cholangitis (P = .011).

172 (P = 0.01, HR = 1.6) and primary sclerosing cholangitis (P = 0.03, HR = 2.9).

173 r samples from control or primary sclerosing cholangitis patients were evaluated for MC markers by qu

174 ive in only about 50%-60% of primary biliary cholangitis patients, with no effective therapy in PSC.

175 ction, particularly among primary sclerosing cholangitis patients.

176 rosing cholangitis (PSC) and primary biliary cholangitis (PBC) are human primary cholangiopathies cha

177 Primary biliary cholangitis (PBC) has been regarded as female-predominan

178 Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune l

179 Primary biliary cholangitis (PBC) is an autoimmune liver disease charact

180 Primary biliary cholangitis (PBC) is an autoimmune liver disease with a

181 n is an important feature of primary biliary cholangitis (PBC) pathogenesis and other cholestatic liv

182 but no clinical evidence of primary biliary cholangitis (PBC), are largely unknown.

183 tical to the pathogenesis of Primary Biliary Cholangitis (PBC), we have analyzed the role of Gal-3 in

184 ade has been associated with primary biliary cholangitis (PBC).

185 redicts long-term outcome in primary biliary cholangitis (PBC).

186 rved in PSC in comparison to primary biliary cholangitis (PBC).

187 tatic liver diseases such as primary biliary cholangitis (PBC, previously referred to as primary bili

188 thies (biliary atresia [BA], primary biliary cholangitis [PBC], and primary sclerosing cholangitis [P

189 ied medical treatment for primary sclerosing cholangitis; pilot studies suggest a possible role for t

190 Since 2008, she showed mild cholangitis possibly caused by sirolimus.

191 tis noted that patients with IgG4-associated cholangitis presented with obstructive jaundice and had

192 After adjusting for the variables acute cholangitis prior to ERC and incomplete biliary drainage

193 fined xenobiotic-induced model of autoimmune cholangitis prompted us to use these reagents and the mo

194 The prevalence of primary sclerosing cholangitis (PSC) among patients with inflammatory bowel

195 during the progression of primary sclerosing cholangitis (PSC) and is characterized by accumulation o

196 Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC)

197 Patients with primary sclerosing cholangitis (PSC) are at an increased risk for cholangio

198 Patients with primary sclerosing cholangitis (PSC) are at increased risk for developing c

199 liary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent autoimmune cholestatic

200 ring systems specific for primary sclerosing cholangitis (PSC) are not validated.

201 iary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) are scarce.

202 er tests in patients with primary sclerosing cholangitis (PSC) but does not improve survival and is a

203 livers for patients with primary sclerosing cholangitis (PSC) due to the weighting of the MELD score

204 60%-80% of patients with primary sclerosing cholangitis (PSC) have concurrent ulcerative colitis (UC

205 varices in patients with primary sclerosing cholangitis (PSC) have not been well studied prospective

206 Primary sclerosing cholangitis (PSC) is a chronic bile duct disease affecti

207 Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease that

208 Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease

209 Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorde

210 Primary sclerosing cholangitis (PSC) is a chronic fibroinflammatory syndrom

211 Primary sclerosing cholangitis (PSC) is a chronic, fibroinflammatory cholan

212 Primary sclerosing cholangitis (PSC) is a chronic, idiopathic, fibroinflamm

213 Primary sclerosing cholangitis (PSC) is a rare progressive disorder leading

214 Primary sclerosing cholangitis (PSC) is a rare, but serious, cholestatic di

215 Primary sclerosing cholangitis (PSC) is a severe liver disease of unknown e

216 Primary sclerosing cholangitis (PSC) is an incurable cholangiopathy of unkn

217 BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary disorder as

218 Patients with primary sclerosing cholangitis (PSC) may be at higher risk of malignancy af

219 Pathogenesis of primary sclerosing cholangitis (PSC) may involve impaired bile acid (BA) ho

220 ormation in patients with primary sclerosing cholangitis (PSC) or after liver transplantation (LTx) r

221 ally in cholangiocytes of primary sclerosing cholangitis (PSC) patients and in mice subjected to DDC

222 Primary sclerosing cholangitis (PSC) patients pose a particularly difficult

223 Primary sclerosing cholangitis (PSC) patients suffer from comorbidities una

224 publications on juvenile primary sclerosing cholangitis (PSC) published over the past 5 years.

225 The pathogenesis of primary sclerosing cholangitis (PSC) remains poorly understood.

226 For patients with primary sclerosing cholangitis (PSC) suffering from bacterial cholangitis,

227 Primary sclerosing cholangitis (PSC) was present in 31/126 CCA patients, of

228 Primary sclerosing cholangitis (PSC), age, history of cholecystectomy, and

229 ding 28 with PBC, 13 with primary sclerosing cholangitis (PSC), and 18 healthy controls.

230 biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and alcoholic liver disease (ALD).

231 veral conditions, such as primary sclerosing cholangitis (PSC), are risk factors.

232 from patients with AP or primary sclerosing cholangitis (PSC), as well as from mice.

233 ural history of pediatric primary sclerosing cholangitis (PSC), autoimmune sclerosing cholangitis (AS

234 In primary sclerosing cholangitis (PSC), bile fluid is frequently colonized wi

235 ase may be accompanied by primary sclerosing cholangitis (PSC), but seldom primary biliary cirrhosis

236 y biliary cholangitis and primary sclerosing cholangitis (PSC), evolve over time with anatomically an

237 Primary sclerosing cholangitis (PSC), first described in the mid-1850s, is

238 liary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment or disrupt

239 n animal models and human primary sclerosing cholangitis (PSC).

240 activity and prognosis in primary sclerosing cholangitis (PSC).

241 ry injury is a feature of primary sclerosing cholangitis (PSC).

242 nign disease, tumour, and primary sclerosing cholangitis (PSC).

243 nt of adult patients with primary sclerosing cholangitis (PSC).

244 eference for diagnosis of primary sclerosing cholangitis (PSC).

245 giopathies, in particular primary sclerosing cholangitis (PSC).

246 e course in patients with primary sclerosing cholangitis (PSC).

247 no information exists in primary sclerosing cholangitis (PSC).

248 ell studied in those with primary sclerosing cholangitis (PSC).

249 acid (UDCA) for treating primary sclerosing cholangitis (PSC).

250 liary cirrhosis (PBC) and primary sclerosing cholangitis (PSC).

251 matory diseases including primary sclerosing cholangitis (PSC).

252 scence has been linked to primary sclerosing cholangitis (PSC).

253 n 9%-15% of patients with primary sclerosing cholangitis (PSC); it is not clear whether this increase

254 highest in patients with primary sclerosing cholangitis (PSC; 22% at 10 years) or alcohol-related li

255 cirrhosis (PBC; n=3052), primary sclerosing cholangitis (PSC; n=3854), hepatitis C virus (HCV; n=15,

256 ry cholangitis [PBC], and primary sclerosing cholangitis [PSC]), we built a comprehensive platform of

257 r 12 months in patients with primary biliary cholangitis resulted in decreases from baseline in alkal

258 logy samples from patients with IgG4-related cholangitis revealed increased levels of IL-13 mRNA, com

259 y; down-regulation of AE2 in primary biliary cholangitis sensitizes cholangiocytes to apoptotic insul

260 HCC) (SMR 38.4-18.8), and primary sclerosing cholangitis (SMR 11.0-4.2), and deterioration in alcohol

261 using RC, FISH, age, and primary sclerosing cholangitis status can be used to estimate the probabili

262 ISH, suspicious cytology, primary sclerosing cholangitis status, and age were associated with carcino

263 unexpectedly developed a more severe form of cholangitis than controls (dnTGF-betaRII mice) and had a

264 to the development of a more severe form of cholangitis than observed in control mice, which is in c

265 TGFbetaRII) spontaneously develop autoimmune cholangitis that resembles human primary biliary cirrhos

266 One patient was diagnosed with cholangitis that responded to intravenous antibiotics an

267 nd dnTGF-betaRII mice, a model of autoimmune cholangitis, the expression of Gal3, NLRP3, and the adap

268 In contrast to previous mouse models of cholangitis, this model displayed a strong sexual dimorp

269 s from dnTGFbetaRII mice transfer autoimmune cholangitis to Rag1(-/-) recipients.

270 F-betaRII) mice, a mouse model of autoimmune cholangitis, to address the therapeutic efficacy of B-ce

271 lcoholic steatohepatitis, primary sclerosing cholangitis, total parenteral nutrition-associated liver

272 in biliary lithiasis and primary sclerosing cholangitis, two cholangiopathies regarded as risk facto

273 zed with 2-octynoic acid manifest autoimmune cholangitis, typical mitochondrial autoantibodies, incre

274 mmatory bowel disease and primary sclerosing cholangitis underscores the need to further understand t

275 we report a novel mouse model of autoimmune cholangitis via immunization with syngeneic bile duct pr

276 Cirrhosis not related to primary sclerosing cholangitis was associated with both intrahepatic and pe

277 Acute experimental cholangitis was induced by adoptive transfer of OVA-spec

278 Primary sclerosing cholangitis was more strongly associated with perihilar

279 ory bowel disease without primary sclerosing cholangitis was not associated with any CCA subtype.

280 ty of research studies on primary sclerosing cholangitis was noted in this review and future research

281 , it remained unclear whether the autoimmune cholangitis was secondary to an intrinsic function withi

282 ecipients, female sex and primary sclerosing cholangitis were associated with improved survival, wher

283 nd those with concomitant primary sclerosing cholangitis were at increased risk.

284 ients suspected to have secondary sclerosing cholangitis were excluded.

285 ile neutropenia, intestinal perforation, and cholangitis-were reported by one patient each.

286 cific antigen migrate to the liver and cause cholangitis when they recognize the same antigen on chol

287 matory disorders (such as primary sclerosing cholangitis), whereas it decreases when patients take dr

288 ual dimorphism: female mice developed marked cholangitis, whereas male mice were resistant to cholang

289 icularly in patients with primary sclerosing cholangitis, who are at risk of developing the disease.

290 are to grant exception points for recurrent cholangitis with >/= 2 episodes of bacteremia or >/= 1 e

291 promoter develop both colitis and autoimmune cholangitis with elevated serum levels of IL-6.

292 ary biliary cirrhosis and primary sclerosing cholangitis with genes encoding major histocompatibility

293 ancreatic pseudotumour, n = 7; e) Sclerosing cholangitis with hepatic pseudotumour, n = 3; f) Scleros

294 patients with and without primary sclerosing cholangitis with higher levels of sensitivity than UroVy

295 titis, n = 4; d) Sclerosing pancreatitis and cholangitis with pancreatic pseudotumour, n = 7; e) Scle

296 RPRETATION: In patients with primary biliary cholangitis with pruritus, 14 days of ileal bile acid tr

297 ter (IBAT), in patients with primary biliary cholangitis with pruritus.

298 ological and clinical features of autoimmune cholangitis with similarities to primary biliary cirrhos

299 Sclerosing cholangitis with strong autoimmune features is particula

300 ibodies (AMAs) and development of autoimmune cholangitis would be found in mice genetically deficient